Page last updated: 2024-11-13
ulixacaltamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Z944: a T-type calcium channel antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 44540045 |
| CHEMBL ID | 3934636 |
| CHEBI ID | 194339 |
| SCHEMBL ID | 4271563 |
Synonyms (31)
| Synonym |
|---|
| FT-0664015 |
| n-({1-[2-(tert-butylamino)-2-oxoethyl]piperidin-4-yl}methyl)-3-chloro-5-fluorobenzamide |
| CHEBI:194339 |
| z944 |
| ulixacaltamida |
| z-944 |
| z 944 |
| 1199236-64-0 |
| ulixacaltamide |
| ulixacaltamidum |
| n-((1-(2-(tert-butylamino)-2-oxoethyl)piperidin-4-yl)methyl)-3-chloro-5-fluorobenzamide |
| prax-944 |
| prax944 |
| gtpl7718 |
| n-[[1-[2-(tert-butylamino)-2-oxoethyl]piperidin-4-yl]methyl]-3-chloro-5-fluorobenzamide |
| SCHEMBL4271563 |
| DTXSID60659275 |
| AKOS027446732 |
| CHEMBL3934636 , |
| bdbm50192689 |
| 4-[[(3-chloro-5-fluorobenzoyl)amino)methyl]-n-(1,1-dimethylethyl)-1-piperidineacetamide |
| Q27089278 |
| 4-(((3-chloro-5-fluorobenzoyl)amino)methyl)-n-(1,1-dimethylethyl)-1-piperidineacetamide |
| QT2PJH89C3 , |
| ulixacaltamide [inn] |
| 1-piperidineacetamide, 4-(((3-chloro-5-fluorobenzoyl)amino)methyl)-n-(1,1-dimethylethyl)- |
| DZR , |
| MS-26311 |
| unii-qt2pjh89c3 |
| CS-0078307 |
| HY-120546 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
| Role | Description |
|---|---|
| T-type calcium channel blocker | Any agent that interferes with the activity of T-type calcium channels. |
| non-narcotic analgesic | A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (5)
| Class | Description |
|---|---|
| piperidines | |
| benzamides | |
| monochlorobenzenes | Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine. |
| monofluorobenzenes | Any member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent. |
| secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (3)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Voltage-dependent T-type calcium channel subunit alpha-1G | Homo sapiens (human) | IC50 (µMol) | 0.0370 | 0.0370 | 0.8915 | 2.5000 | AID1316446; AID1325717 |
| Voltage-dependent T-type calcium channel subunit alpha-1H | Homo sapiens (human) | IC50 (µMol) | 0.0730 | 0.0320 | 1.0479 | 3.6000 | AID1316439; AID1325718 |
| Voltage-dependent T-type calcium channel subunit alpha-1I | Homo sapiens (human) | IC50 (µMol) | 0.0860 | 0.0860 | 0.6547 | 2.5000 | AID1316437; AID1325719 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (29)
Molecular Functions (9)
Ceullar Components (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoplasm | Voltage-dependent T-type calcium channel subunit alpha-1G | Homo sapiens (human) |
| plasma membrane | Voltage-dependent T-type calcium channel subunit alpha-1G | Homo sapiens (human) |
| synapse | Voltage-dependent T-type calcium channel subunit alpha-1G | Homo sapiens (human) |
| voltage-gated calcium channel complex | Voltage-dependent T-type calcium channel subunit alpha-1G | Homo sapiens (human) |
| plasma membrane | Voltage-dependent T-type calcium channel subunit alpha-1H | Homo sapiens (human) |
| membrane | Voltage-dependent T-type calcium channel subunit alpha-1H | Homo sapiens (human) |
| voltage-gated calcium channel complex | Voltage-dependent T-type calcium channel subunit alpha-1H | Homo sapiens (human) |
| plasma membrane | Voltage-dependent T-type calcium channel subunit alpha-1I | Homo sapiens (human) |
| voltage-gated calcium channel complex | Voltage-dependent T-type calcium channel subunit alpha-1I | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (9)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1325719 | Inhibition of human CaV 3.3 by manual patch clamp assay | 2016 | Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23 | Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers. |
| AID1316446 | Inhibition of T-type calcium channel Cav3.1 (unknown origin) expressed in HEK293 cells assessed as calcium influx by Fluo-4-AM dye-based FLIPR assay | 2016 | Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18 | Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers. |
| AID1316439 | Inhibition of recombinant T-type calcium channel Cav3.2 (unknown origin) expressed in HEK293 cells assessed as inhibition of CaCl2-induced calcium influx preincubated for 3 mins prior CaCl2 addition by Fluo-4-AM dye-based FLIPR assay | 2016 | Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18 | Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers. |
| AID1325718 | Inhibition of human CaV 3.2 by manual patch clamp assay | 2016 | Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23 | Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers. |
| AID1325717 | Inhibition of human CaV 3.1 by manual patch clamp assay | 2016 | Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23 | Structure-Activity Relationship, Drug Metabolism and Pharmacokinetics Properties Optimization, and in Vivo Studies of New Brain Penetrant Triple T-Type Calcium Channel Blockers. |
| AID1316437 | Inhibition of T-type calcium channel Cav3.3 (unknown origin) expressed in HEK293 cells assessed as calcium influx by Fluo-4-AM dye-based FLIPR assay | 2016 | Journal of medicinal chemistry, Sep-22, Volume: 59, Issue:18 | Preparation, Antiepileptic Activity, and Cardiovascular Safety of Dihydropyrazoles as Brain-Penetrant T-Type Calcium Channel Blockers. |
| AID1346702 | Human Cav3.3 (Voltage-gated calcium channels) | 2012 | Science translational medicine, Feb-15, Volume: 4, Issue:121 | T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. |
| AID1346720 | Human Cav3.2 (Voltage-gated calcium channels) | 2012 | Science translational medicine, Feb-15, Volume: 4, Issue:121 | T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. |
| AID1346719 | Human Cav3.1 (Voltage-gated calcium channels) | 2012 | Science translational medicine, Feb-15, Volume: 4, Issue:121 | T-type calcium channel blockers that attenuate thalamic burst firing and suppress absence seizures. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (88.24) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 41.41
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (41.41) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||